Patents by Inventor Michael E. Garst

Michael E. Garst has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10301269
    Abstract: The present invention relates to imidazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: May 28, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, Michael E. Garst
  • Patent number: 10287243
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: May 14, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
  • Publication number: 20190127319
    Abstract: The present disclosure relates to phenyl urea derivatives useful for the treatment of inflammatory diseases, pharmaceutical compositions containing them and their use as modulators of the N-formyl peptide receptor (FPR), including FPR1 and FPR2, or as selective agonists of the FPR1 receptor.
    Type: Application
    Filed: March 28, 2017
    Publication date: May 2, 2019
    Inventors: Tien T. Duong, Richard L. Beard, Michael E. Garst
  • Patent number: 10172832
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: April 10, 2018
    Date of Patent: January 8, 2019
    Assignee: ALLERGAN, INC.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Publication number: 20180344692
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Application
    Filed: August 7, 2018
    Publication date: December 6, 2018
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • Patent number: 10077289
    Abstract: The present invention relates to novel cyclosporin analogs, processes for preparing them, pharmaceutical compositions containing them, and methods for using these analogs and the compositions containing them for the treatment of medical conditions, including but not limited to ocular conditions such as dry eye.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: September 18, 2018
    Assignee: Allergan, Inc.
    Inventors: Simon N. Pettit, Andrew D. Jones, Catherine Simone V. Frydrych, Alex J. Thomas, Michael E. Garst
  • Patent number: 10065992
    Abstract: Disclosed herein are novel analogs of cyclosporin, pharmaceutical compositions containing them, and methods for their use in the treatment of dry eye and other conditions.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: September 4, 2018
    Assignee: Allergan, Inc.
    Inventors: Catherine Simone Victoire Frydrych, William Robert Carling, Michael E. Garst, Michael E. Stern, Christopher S. Schaumburg
  • Publication number: 20180228772
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Application
    Filed: April 10, 2018
    Publication date: August 16, 2018
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 9974772
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Grant
    Filed: January 18, 2017
    Date of Patent: May 22, 2018
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Publication number: 20180094031
    Abstract: The present invention relates to cyclosporin analogs that are potent inhibitors of cyclophilin D and have low immunosuppressive activity; processes for preparing them; pharmaceutical compositions containing them; and methods for using these analogs and compositions containing them for the treatment of medical conditions, including but not limited to ischemic conditions, such as ischemia-reperfusion (I/R) injury, including myocardial FR injury, cerebral I/R injury, and ocular or retinal I/R injury.
    Type: Application
    Filed: December 5, 2017
    Publication date: April 5, 2018
    Inventors: Simon N. Pettit, Andrew D. Jones, Catherine Simone V. Frydrych, Alex J. Thomas, Michael E. Garst
  • Patent number: 9926264
    Abstract: The present invention relates to N-phenyl carbamate derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide 2 receptor.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: March 27, 2018
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien T. Duong, Michael E. Garst
  • Patent number: 9920013
    Abstract: The present invention relates to 1-(2,5-dioxoimidazolidin-1-yl)-3-substituted urea compounds, processes for preparing them, pharmaceutical compositions containing them, their use as pharmaceuticals as modulators of the FPR2 receptor, and to methods of treating inflammatory diseases or conditions in a subject in need thereof by administering the compound(s) or pharmaceutical composition to the subject.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: March 20, 2018
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Vidyasagar Vuligonda, Thong Huy Vu, Michael E. Garst
  • Publication number: 20180071260
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Application
    Filed: November 21, 2017
    Publication date: March 15, 2018
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • Patent number: 9914755
    Abstract: The present invention relates to cyclosporin analogs that are potent inhibitors of cyclophilin D and have low immunosuppressive activity; processes for preparing them; pharmaceutical compositions containing them; and methods for using these analogs and compositions containing them for the treatment of medical conditions, including but not limited to ischemic conditions, such as ischemia-reperfusion (I/R) injury, including myocardial FR injury, cerebral I/R injury, and ocular or retinal I/R injury.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: March 13, 2018
    Assignee: Allergan, Inc.
    Inventors: Simon N. Pettit, Andrew D. Jones, Catherine Simone V. Frydrych, Alex J. Thomas, Michael E. Garst
  • Patent number: 9849113
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: December 26, 2017
    Assignee: Allergan, Inc.
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • Publication number: 20170172982
    Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, acute, neuropathic and chronic.
    Type: Application
    Filed: March 1, 2017
    Publication date: June 22, 2017
    Inventors: Daniel W. Gil, John E. Donello, Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha
  • Patent number: 9670190
    Abstract: The present invention relates to novel pyridine or pyrimidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors. The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat disorders associated with chemokine receptor modulation.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: June 6, 2017
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, John E. Donello, Veena Viswanath, Michael E. Garst, Haiqing Yuan, Xiaoxia Liu
  • Patent number: 9670150
    Abstract: The present invention relates to (2-ureidoacetamido)alkyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor 2.
    Type: Grant
    Filed: April 16, 2013
    Date of Patent: June 6, 2017
    Assignee: Allergan, Inc.
    Inventors: Richard L. Beard, Tien Duong, John E. Donello, Veena Viswanath, Michael E. Garst
  • Patent number: 9663460
    Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: May 30, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Haiqing Yuan, Richard L. Beard, Michael E. Garst, John E. Donello, Xiaoxia Liu, Veena Viswanath
  • Publication number: 20170119737
    Abstract: The present invention relates to novel amide derivatives of N-urea substituted amino acids, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor like-1 (FPRL-1) receptor.
    Type: Application
    Filed: January 18, 2017
    Publication date: May 4, 2017
    Inventors: Richard L. Beard, Tien T. Duong, John E. Donello, Veena Viswanath, Michael E. Garst